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Abstract
The inaccuracy of routine serum 25-hydroxyvitamin D measurements hampers the interpretation 
of data in patient care and public health research. We developed and validated a candidate 
reference measurement procedure (RMP) for highly accurate quantitation of two clinically 
important 25-hydroxyvitamin D metabolites in serum, 25-hydroxyvitamin D2 [25(OH)D2] and 25-
hydroxyvitamin D3 [25(OH)D3]. The two compounds of interest together with spiked deuterium-
labeled internal standards [d3-25(OH)D2 and d6-25(OH)D3] were extracted from serum via liquid-
liquid extraction. The featured isotope-dilution LC-MS/MS method used reversed-phase 
chromatography and atmospheric pressure chemical ionization in positive ion mode. A 
pentafluorophenylpropyl-packed UHPLC column together with isocratic elution allowed for 
complete baseline resolution of 25(OH)D2 and 25(OH)D3 from their structural C-3 isomers within 
12 min. We evaluated method trueness, precision, potential interferences, matrix effects, limits of 
quantitation, and measurement uncertainty. Calibration materials were, or were traceable to, NIST 
Standard Reference Materials 2972. Within-day and total imprecision (CV) averaged 1.9% and 
2.0% for 25(OH)D3, respectively, and 2.4% and 3.5% for 25(OH)D2, respectively. Mean trueness 
was 100.4% for 25(OH)D3 and 100.3% for 25(OH)D2. The limits of quantitation/limits of 
detection were 4.61/1.38 nmol/L for 25(OH)D3 and 1.46/0.13 nmol/L for 25(OH)D2. When we 
compared our RMP results to an established RMP using 40 serum samples, we found a 
nonsignificant mean bias of 0.2% for total 25(OH)D. This candidate RMP for 25(OH)D 
metabolites meets predefined method performance specifications (≤5% total CV and ≤1.7% bias) 
and provides sufficient sample throughput to meet the needs of the Centers for Disease Control 
and Prevention Vitamin D Standardization Certification Program.
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Introduction
Vitamin D is important for bone health [1] and over the years research has focused on 
additional health benefits such as those relative to improved muscle strength, and reduced 
risks for cancer and type 2 diabetes [2]. Vitamin D status is routinely assessed in patient care 
using serum or plasma concentrations of the longer-lived 25-hydroxyvitamin D [25(OH)D] 
metabolites. 25(OH)D represents the sum of 25(OH)D2, a liver metabolite derived from 
vitamin D2, which is obtained from dietary sources (plant and fortified foods and dietary 
supplements) or prescribed medication, and 25(OH)D3, another liver metabolite derived 
from vitamin D3 formed endogenously in the skin by exposure to sunlight or obtained 
through dietary sources (animal and fortified foods and dietary supplements).
The most commonly used analytical methods to measure 25(OH)D metabolites are based on 
immunoassays (e.g., chemiluminescent, enzyme-, or radio-labeled) or chromatographic 
assays coupled with different detectors [e.g., ultraviolet (HPLC-UV) or tandem mass 
spectrometry (LC-MS/MS)] [3]. Because competitive immunoassays rely on the interaction 
of 25(OH)D metabolites with antibodies that may lack specificity, this methodology faces 
challenges with interfering compounds [4, 5]. The high degree of specificity of 
chromatographic methods coupled with tandem mass spectrometry makes LC-MS/MS the 
technique of choice for reference measurement procedures (RMP) intended to assign 
25(OH)D3 and 25(OH)D2 target values to materials. Although LC-MS/MS is considered 
highly specific, the accuracy of mass spectrometric measurements can be affected by 
isobaric compounds that require chromatographic separation from the analytes of interest. 
The best known isobaric interference is the C-3 structural analog of 25(OH)D3, 3-
epi-25(OH)D3, which may be found circulating in substantial quantities [6] but does not 
possess the full range of biological activities of 25(OH)D3.
The inadequate accuracy of 25(OH)D measurements [5, 7, 8] hampers the interpretation of 
data in patient care and public health research. To minimize this problem a reference 
measurement system is needed that consists of RMPs [9, 10] and higher order standard 
reference materials (SRM) [11]. Worldwide, vitamin D standardization activities are 
ongoing [12–14]. As part of these efforts, the Centers for Disease Control and Prevention 
(CDC) established an international Vitamin D Standardization Certification Program 
(VDSCP) [15] to improve the accuracy and reliability of 25(OH)D laboratory testing. This 
program uses approaches and procedures successfully employed in CDC’s Hormone 
Standardization Program [16, 17]. The program provides serum materials with 25(OH)D 
values assigned using a RMP. These materials are used to assess and improve assay 
calibration, and to verify assay accuracy through blinded challenges. Currently, two RMPs 
for quantitation of 25(OH)D in serum have been reviewed and accepted by the Joint 
Committee for Tractability in Laboratory Medicine (JCTLM) [9, 10], with one of the 
methods being primarily used for the certification of SRM materials [9]. To meet the 
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growing demands for RMP services, such as providing 25(OH)D value assignment to a large 
number of serum materials for assessing measurement accuracy and reliability, we 
developed and validated a candidate RMP for serum 25(OH)D3 and 25(OH)D2 
measurements using isotope dilution LC-MS/MS. This method is designed to assign 
reference values to serum materials at the highest level of accuracy and metrological 
traceability [18, 19]. We aimed to develop a metrologically traceable reference method that 
achieved optimum trueness and precision by meeting the suggested specifications for a RMP 
for 25(OH)D metabolites [20].
Materials and methods
Chemicals and reagents
The following chemicals were purchased: 25(OH)D3 from U.S. Pharmacopeial Convention 
(Rockville, MD); 25-hydroxycholesterol, 25(OH)D2, and 1-α-hydroxyvitamin D3 from 
Sigma Aldrich (St. Louis, MO); 7,19,19-trideuterium-25-hydroxyvitamin D2 (d3-25(OH)D2) 
and 3-epi-25(OH)D3 from IsoSciences (King of Prussia, PA); 7-α-hydroxy-cholesten-3-one 
and 4β-hydroxycholesterol from Santa Cruz Biotechnology (Santa Cruz, CA); and 24-
hydroxycholesterol from Enzo Life Sciences (Farmingdale, NY). 26, 26, 26, 27, 27, 27-
Hexadeuterium-25-hydroxyvitamin D3 (d6-25(OH)D3) and 27-hydroxycholesterol were 
purchased from Medical Isotopes (Pelham, NH). 3-Epi-25(OH)D2 was a gift from the 
National Institute of Standards and Technology (NIST, Gaithersburg, MD). ACS grade 
methanol and n-hexane were obtained from Burdick & Jackson (Muskegan, MI). ASC/USP 
grade ethanol was purchased from Pharmco-AAPER (Brookfield, CT). Purified water (18 
MΩ) was obtained from an Aqua Solutions water purification system (Aqua Solutions, Inc., 
Falmouth, ME). SRM 2972 (25(OH)D2 and 25(OH)D3, solvent-based) and SRM 972a 
(serum-based) were purchased, and SRM 972 (2 levels, serum-based) was a gift from NIST.
Calibration preparation and control materials
Volumetric steps were gravimetrically controlled, where indicated, using a Mettler-Toledo 
XP205 analytical balance (Mettler-Toledo LLC, Columbus, OH) equipped with a built-in 
antistatic electrode. All solutions of standards were made using absolute ethanol. A master 
stock solution for 25(OH)D3 was gravimetrically prepared by dissolving solid material in 
absolute ethanol to achieve a concentration of approximately 30–50 μmol/L. Three working 
standard 25(OH)D3 solutions (targeted range: 150–250 nmol/L) were gravimetrically 
prepared from the master stock solution and their exact concentrations were determined by 
comparison with gravimetrically diluted primary reference material SRM 2972 [21] (see 
Electronic Supplementary Material for details). We gravimetrically added 25(OH)D2 from 
SRM 2972 to each 25(OH)D3 working standard solution to achieve a targeted range of 
25(OH)D2 of 20–40 nmol/L. Master stock solutions of internal standards, d6-25(OH)D3 and 
d3-25(OH)D2, were made in absolute ethanol to achieve 150 and 60 μmol/L, respectively, 
based on UV measurements at 265 nm using molar extinction coefficients of 18,300 and 
19,400 L mol−1cm−1, respectively. Working internal standard solutions (ISTD) were made 
by gravimetrically combining different amounts from the master stock solutions to achieve 
concentrations ranging between 70–90 and 10–12 nmol/L, for d6-25(OH)D3 and 
d3-25(OH)D2, respectively. For each measurement series, two sets of four working 
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calibrators were gravimetrically prepared from two independent working standard solutions 
and mixed with ISTD (0.5 mL) to achieve mass ratios of unlabeled to labeled standards of 
approximately 0.25, 0.50, 1.25, 2.5, resulting in total of 8 different calibration levels for each 
anlyte. Calibrators were evaporated under vacuum (SpeedVac Plus, Savant Instrument Co., 
Farmingdale, NY), reconstituted (73% methanol/water), in some cases filtered (0.45 μm 
PVDF, Captiva 96-well filter plate, Agilent Tech., Santa Clara, CA), and finally injected 
directly onto the UHPLC column without additional preparation. For each measurement 
series, we used 3 of the 4 calibration curve levels (from both sets, i.e., 6 calibration points) 
that bracketed the expected values for the serum samples (based on pre-screened 
concentrations determined using a routine LC-MS/MS method [22]). The two most common 
bracketing calibration ranges (3 calibration levels from two independent working standard 
solutions, resulting in 6 calibration points) were: approximately 10–50 and 20–100 nmol/L 
for 25(OH)D3 and approximately 1–5 and 2–10 nmol/L for 25(OH)D2.
We prepared all internal quality control materials (IQC) from pooled human serum 
purchased from U.S. blood banks. All units were screened for 25(OH)D metabolites and in 
some cases, they were spiked with either 25(OH)D2 or 25(OH)D3, or both, as needed, to 
achieve desired concentrations. All specimens were stored at −70 °C when not in use. Two 
IQC pools had values assigned using an established RMP (Laboratory for Analytical 
Chemistry, University of Ghent, Belgium).
Sample preparation
Volumetric steps were gravimetrically controlled where indicated. Serum was accurately 
weighted (0.25 to 1 g) and added to water (1 mL; to avoid protein precipitation from 
subsequent addition of ethanolic ISTD). To this mixture we gravimetrically added ISTD (0.5 
g) and allowed equilibration for 1 h at room temperature. Aqueous Na2CO3 (0.1 g/mL, 0.1 
mL; pH ~ 11) was added to allow release of 25(OH)D metabolites from binding proteins and 
the analytes of interest were removed from serum via liquid-liquid extraction (LLE) with 
hexane (2.5 mL). To maximize extraction efficiency, the LLE step was repeated, the 
combined organic layers were dried under vacuum at 45 °C, reconstituted in 73% MeOH/
water (0.3 mL), filtered (0.45 μm PVDF), and injected for LC-MS/MS analysis.
LC-MS/MS analysis
We used an Accela UHPLC system coupled to a TSQ Quantum Ultra tandem mass 
spectrometer (both Thermo Fisher Scientific, Waltham, MA) in positive atmospheric 
pressure chemical ionization (APCI) mode for analysis. Isocratic elution (73% MeOH/water 
at 0.45 mL/min) for 12 min on an Ascentis F5 analytical column (2.1 mm × 150 mm, 2.7 
μm, Sigma-Aldrich, St. Louis, MO) held at 27 °C, followed by a short (1–3 min) column 
flush with 100% methanol and short (1–3 min) equilibration to initial conditions, resulted in 
a < 20 min instrument analysis time per sample. The autosampler tray temperature was 
maintained at 7 °C. Injection volume, using partial loop mode, was 30 μL. Mass detection 
was carried out under selected reaction monitoring (SRM) conditions using the following 
transitions: m/z 383.3 → 365.1 (quantitation) and 383.3 → 105.0 (confirmation) for 
25(OH)D3, m/z 395.3 → 377.3 (quantitation) and 395.3 → 209.1 (confirmation) for 
25(OH)D2, m/z 389.3 → 371.1 for d6-25(OH)D3 and m/z 398.3 → 380.3 for d3-25(OH)D2. 
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Scan time was 0.25 sec. Mass resolution in Q1 and Q3 was set at 0.7 full width at half 
maximum. We used Xcalibur 2.0.6 software (Thermo Fisher Scientific) for instrument 
control and data collection and processing.
Data analysis and typical measurement series set-up
In Xcalibur, we built each calibration curve in each measurement series by plotting peak 
area ratios of the analyte quantification ion divided by the ISTD, i.e., response ratio on the y-
axis and the corresponding mass ratio [i.e., the exact weight (g) of the added working 
standard solution multiplied by its mass fraction (ng/g) divided by the exact weight (g) of 
the added ISTD solution multiplied by its mass fraction (ng/g)] on the x-axis. We used linear 
regression with 1/x weighting as curve fit. For details on the calculation of mass fractions 
and mass concentrations, see Electronic Supplementary Material. Details on a typical run set 
up are presented in Electronic Supplementary Material Fig. S1.
Value assignment
For value assignment, we first pre-screened unknown samples using our routine in-house 
LC-MS/MS method [22] to obtain approximate 25(OH)D metabolite concentrations. Then, 
each unknown sample was prepared for the RMP in at least two independent measurements 
series, each consisting of duplicate preparations. It should be noted that all samples 
(calibrators, QC, or unknowns) were injected twice, and thus each individual result was the 
average of duplicate injections. The final concentrations for 25(OH)D3 and 25(OH)D2 were 
assigned from the mean of all measurements.
Method validation
Direct calibration—We assessed whether the calibrators need to be carried through the 
sample preparation procedure or could be directly injected for chromatographic separation 
and detection (see Electronic Supplementary Material for experimental design). We 
evaluated the statistical difference between direct and indirect calibration using Student’s 2-
sided t-test. All statistical evaluations were performed using Analyse-it (version 2.20, 
Analyse-it Software, LTD, Leeds, UK), a statistical plug-in for Microsoft Excel.
Interference—We tested eight structural analogs (with typical mass transitions at or close 
to the m/z values monitored for 25(OH)D3, 25(OH)D2 or the internal standards or capable of 
producing product ions similar to those produced by the analytes of interest) for potential 
interference, among which were the 3-epimer analogs of 25(OH)D3 and 25(OH)D2. All 
compounds were evaluated for their retention time relative to 25(OH)D3 or 25(OH)D2. In 
addition, to assess for potential interferences we monitored the confirmation ion ratio 
(confirmation ion to quantitation ion, CI/QI) for 25(OH)D3 and 25(OH)D2 in 148 serum 
samples, and compared it to the CI/QI ratio of calibration solutions.
Absolute recovery from serum (extraction efficiency)—The recovery of ISTD from 
the sample preparation procedure was studied using a single donor human serum. Two sets 
of six replicates were sampled. To the first set, ISTD was added and the samples were 
carried through the sample preparation procedure as previously described; to the second set, 
the same amount of ISTD was added after the LLE step. The differences in the isotope ratios 
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of the two sets were calculated, to assess absolute recovery of the sample preparation 
procedure.
Limit of quantitation (LOQ) and limit of detection (LOD)—We measured the NIST 
SRM 972 level 1 material (reference concentration 1.46 ± 0.49 nmol/L) in five independent 
measurement series to estimate the LOQ and LOD for 25(OH)D2. Similar to the approach 
used by the Ghent RMP, we defined the LOQ at a total CV <7% [10]. For 25(OH)D3, to 
estimate the LOQ we used two different serum materials (12.0 and 40 nmol/L).We diluted 
one of the serum materials (12 nmol/L) with de-ionized water up to 5 times, resulting in a 
concentration range from 2.1 to 12.0 nmol/L and the second serum material (40 nmol/L) 
approximately 10 and 15 times with de-ionized water, resulting in a concentration range 
from 2.5 to 4.0 nmol/L. The analyses were performed in at least five independent 
measurement series and the SD at the estimated zero concentrations (y-intercept: σ0) from 
the extrapolation of repeated measurements was used to estimate the LOD as 3σ0 and LOQ 
as 10σ0 for 25(OH)D3 [23].
Imprecision and trueness—The method imprecision was determined using five serum 
IQC materials: two preparations per level over five days (n = 10 results). The within-day, 
between-day, and total CV were calculated for each level using CLSI EP-10-A3 as a guide 
[24]. We assessed method trueness using five NIST secondary reference materials, measured 
in singlicate (at least five independent measurement series per material). Trueness was 
expressed as percent difference from the NIST certified value. We also evaluated method 
accuracy by analyzing 40 individual serum samples, which were value assigned by an 
established RMP (Laboratory for Analytical Chemistry, University of Ghent, Belgium) [10]. 
We analyzed these samples in singlicate in six independent measurement series. The mean 
percent bias of the candidate RMP to the certified RMP was determined using Bland-Altman 
agreement and linear regression analyses.
Uncertainty of measurements—The standard uncertainty of a measurement results (uc) 
is a propagation of many uncertainty components (type “A” (random) and “B” (systematic)), 
and also called combined uncertainty. We evaluated potential sources of uncertainty and 
included all factors, which might have a significant contribution, in the calculation of 
standard uncertainty. We calculated the random component of uncertainty from standard 
deviation from repeated independent measurements (n, referred to in the literature as 
repeatability) and used it to calculate the measurement standard deviation of the mean. 
These standard deviations were from three independent measurement series using IQC 
serum materials prepared in duplicate, with concentrations of 25(OH)D3 ranging from 16.4 
to 72.2 nmol/L and for 25(OH)D2 ranging from 3.01 to 17.1 nmol/L. This protocol matches 
the measurement protocol for unknowns. The systematic component of uncertainty was 
calculated from four different factors: uncertainty due to the purity of the primary reference 
material as indicated by NIST (0.8%, SRM 2972, Certificate of Analysis December 07, 
2009), uncertainty from determination of the serum density, determination of the weight of 
each component, and other unspecific interferences (e.g., sample preparation, instrument, 
undetected interferences, 1%). The combined standard uncertainty was calculated as square 
root of combined quadratically type A and B components of uncertainty and then multiplied 
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it by a coverage factor, k (k = 2 for 95% confidence level) to obtain the expanded uncertainty 
(U).
Results and discussion
We developed and validated a candidate RMP with features as described in ISO 15193 for 
reference methods [25] for quantitation of 25(OH)D3 and 25(OH)D2 in serum. This new 
method also meets the suggested performance specifications for a total 25(OH)D RMP of 
maximum total CV of 5% and maximum bias of 1.7% [20].
Sample preparation
As a first step, to obtain approximate 25(OH)D metabolite concentrations, we screened 
unknown samples using our routine in-house LC-MS/MS method [22]. The typical amount 
of sample used with the candidate RMP was 0.5 g, however when the screening 
concentration was above the highest calibrator used in the method, we adjusted the amount 
of sample to less than 0.5 g, and for samples with 25(OH)D2 at the LOQ or slightly above 
we adjusted it to more than 0.5g. The typical amount of serum used by our candidate RMP 
was comparable to that used by the Ghent RMP (250–500 μL) [10], but lower than that used 
by the NIST RMP (2 g) [9]. To avoid protein precipitation, we diluted serum samples with 
water prior to adding the ethanolic ISTD. 25(OH)D metabolites are usually released from 
the vitamin D binding protein (the main carrier of these lipophilic compounds) via extreme 
pH change [26] or by mechanical shaking with extraction solvents. We used LLE with 
hexane at basic pH (> 10). As a potentially faster alternative to LLE, we also evaluated 
supported liquid extraction (SLE). To assure adequate detection of the less abundant 
25(OH)D2 metabolite, the SLE cartridges required at least twice as much sample volume 
compared to our LLE procedure (data not shown). Two additional drawbacks of SLE 
cartridges were its higher cost and its need for larger volumes of organic solvents compared 
to LLE. After LLE, the serum samples were re-dissolved in 73% MeOH/water, which 
typically produced cloudy samples as a result of reduced solubility of fat soluble compounds 
extracted with hexane in the LLE step. During method development, we incorporated a 
filtration step (0.45 μm PVDF) to produce clean extracts for UHPLC. Although this step 
reduced extraction efficiency by a few percent, it substantially extended column life and is 
routinely used.
Calibration
NIST provides the highest order commercially available primary calibration reference 
materials for 25(OH)D3 and 25(OH)D2 [24]. To calibrate, we used primary reference 
material NIST SRM 2972 [for 25(OH)D2] or solutions traceable to SRM 2972 [for 
25(OH)D3]. Most reported RMPs use calibration where the mass ratio of the unlabeled 
(compound of interest) to labeled (ISTD) analyte is close to 1, at which the best 
measurement precision is achievable [27]. For example, the NIST 25(OH)D JCTLM-
accepted RMP uses a 6-point calibration curve with mass ratios between 0.65 and 1.4 [9] 
while the Ghent method uses a 1-point calibration curve with a ± 25% deviation from the 
typical mass ratio of 1 [10]. We used a 6-point bracketing calibration curve with 
approximate mass ratio ranges from 0.25 to 1.25 [for 25(OH)D3 and 25(OH)D2 
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concentrations in the unknown samples < 75 nmol/L and < 10 nmol/L, respectively]. When 
the pre-screened concentrations of 25(OH)D3 and 25(OH)D2 were above 75 nmol/L and 10 
nmol/L, respectively, the calibration curves had a mass ratio range of approximately 0.5 to 
2.5. To achieve that, we varied the amount of working standard solution, while keeping the 
amount of ISTD the same. Our approach allowed for simplified sample preparation because 
it did not require individual ISTD concentration adjustment to match the endogenous 
25(OH)D3 and 25(OH)D2 concentration individually for each serum sample. Wider mass 
calibration ranges with multipoint calibration curves have previously been reported for 
JCTLM-accepted RMPs, e.g., for cholesterol analysis [28] and also in a recently reported 
candidate RMP for cyclosporine A [29].
We directly analyzed ethanol-based calibrators mixed with the ISTD without carrying them 
through the sample preparation procedure. To justify the direct use of calibrators, we 
assessed whether a directly analyzed calibration set provided different results to a set 
submitted to sample preparation. The mean relative response ratios from the two sets were 
not statistically significantly different using a two-sided Student’s t-test [−0.2% difference 
for 25(OH)D2 (P = 0.84) and 0.6% difference for 25(OH)D3 (P = 0.39)], and thus, we 
considered the direct use of calibrators without subjecting them to sample preparation as 
appropriate. We obtained linear calibration curves for both analytes with high coefficients of 
determination, R2 > 0.995. A typical regression line was yresponse ratio = 0.9218 xmass ratio 
+ 0.00445 (R = 0.9997, standard error = 0.0100; n=12) and yresponse ratio= 1.6847xmass ratio 
+ 0.03346 (R = 0.9990; standard error = 0.0319; n=12) for 25(OH)D3 and 25(OH)D2, 
respectively. We also obtained good method precision and minimal bias with this calibration 
approach (shown later).
Interference testing
Another important concern was the assessment of potential interferences from isobaric 
compounds. The C3-epimer form of 25(OH)D3 can be present in significant quantities in 
serum, especially in specimens with high circulating concentrations of 25(OH)D3 [6]. To 
avoid overestimation of circulating 25(OH)D3, it is therefore important that the epimer be 
chromatographically resolved. Our candidate RMP used a reversed-phase 
pentafluorophenylpropyl column with isocratic elution, which provided complete baseline 
resolution of 25(OH)D3 from 3-epi-25(OH)D3 (Fig. 1) and 25(OH)D2 from 3-epi-25(OH)D2 
(chromatographic data not shown), with relative retention times for both epimers of greater 
than 1.10 (Table 1). We tested six additional structural analogs known to be present in serum 
with similar molecular masses to the analytes of interest. The relative retention times of 
these potential interferents were greater than 1.5, which indicated that their presence is not 
likely to affect our method (Table 1).
As compared to the other two JCTLM accepted RMPs for 25(OH)D metabolites, our LC-
MS/MS method offers an additional degree of specificity because it can identify potential 
interferences in serum specimens by monitoring the peak area ratio from two m/z transitions 
for each analyte. We established acceptability limits for the confirmation ion ratio (peak area 
ratio of confirmation to quantitation ion) using pure calibration materials (Table 2). We 
chose variation ranges for the ion ratios of ± 15% for 25(OH)D3 and ± 20% for 25(OH)D2. 
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We accepted a wider range for 25(OH)D2, because of its typical low abundance in serum, 
resulting in significantly lower confirmation ion peak areas, and thus introducing more 
variability to the ion ratio calculations. Our choices met or exceeded common “industry 
standards” for ion ratios. The European Commission uses ± 20–50% depending of the 
abundance of each ion [30] and the Society of Forensic Toxicologists uses ± 20–30% [31], 
but we were less stringent than criteria from the U.S. Food and Drug Administration, which 
uses ± 10% [32]. Our criteria were in line with a recent accepted RMP, which allowed for 
± 20% ion ratio variation for measurement of low abundance serum analytes [33]. When we 
applied the established limits to 25(OH)D3 results from 148 serum samples and to 
25(OH)D2 results from 67 serum samples (with concentrations greater than the LOQ), 100% 
and 98.5% of the samples met the predetermined limits for 25(OH)D3 and 25(OH)D2, 
respectively (Table 2).
Lastly, we assessed potential interferences due to a carry-over effect from a previous sample, 
by injecting mobile phase after a high concentration calibrator (140 nmol/L). We did not 
observe any signal in the monitored mass transitions in the mobile phase blank, thus 
indicating no evidence of carry-over from a previous injection (data not shown).
Absolute recovery from serum
We assessed the effect of matrix on analyte recovery during the sample preparation 
procedure. Based on the difference in response ratios from the addition of ISTD prior to and 
after sample preparation, our extraction method yielded a mean absolute recovery from the 
sample preparation procedure ± 2-sided confidence interval from replicate analyses of 91% 
± 1.4% for 25(OH)D3 and 95% ± 1.2% for 25(OH)D2. This was similar or higher compared 
to the absolute recovery of the extraction method reported for 25(OH)D3 and 25(OH)D2 by 
the NIST RMP (97% and 92%, respectively) [9] and the Ghent RMP (71% and 70%, 
respectively) [10]. Optimizing the sample preparation steps to maximize the recovery from 
LLE ensures better detection, an aspect that is especially important for 25(OH)D2, typically 
present in serum at low concentrations.
Limit of quantitation (LOQ) and limit of detection (LOD)
The LOQ for 25(OH)D2 was assessed using SRM 972 level 1 by an approach similar to the 
one used by the University of Ghent in their JCTLM-accepted RMP [10]. The estimated 
mean for this material from analysis (n = 5 independent measurement series) with the 
candidate RMP was 1.25 ± 0.08 nmol/L (2-sided 95% CI) with an absolute difference from 
the target of −0.21 nmol/L, total CV of 6.1%, and mean signal-to noise (S/N) ratio of 28. 
The estimated mean was within the NIST uncertainty reported for this level and the CV met 
the set imprecision criteria. Based on these data, we set the LOQ for 25(OH)D2 to be 1.46 
nmol/L, which is the reference value for 25(OH)D2 in this SRM material (1.46 ± 0.49 
nmol/L). The LOD for 25(OH)D2 was estimated to be 0.13 nmol/L, at a S/N ratio of 3. For 
25(OH)D3, we used a different approach, for which we diluted two serum materials to 
concentrations close to the expected LOD (based on S/N). The LOQ and LOD for 
25(OH)D3 were estimated to be 4.61 nmol/L (CV = 2.9%; S/N ~100) and 1.38 nmol/L (CV 
~70%; S/N ~20), respectively [23]. In the end, serum concentrations 25(OH)D3 are rarely 
less than 10 nmol/L and the absolute LOQ and LOD estimates are inconsequential. Our 
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candidate RMP met the widened imprecision goal of <7% CV at the LOQ for both analytes. 
The LOQ values of the candidate RMP are sufficiently low to assign target values to 
unknown serum samples; they are also commensurate with LOQ values reported by the two 
accepted RMPs [9, 10].
Precision and trueness
Our candidate RMP is intended for target value assignment, not for routine measurement of 
unknown samples and therefore has to comply with stricter performance criteria. Thus, we 
assessed method imprecision and bias against performance criteria recommended for a 25-
hydroxyvitamin D RMP, namely, total CV ≤ 5% and a systematic bias of ≤ 1.7% [13, 20]. 
The mean within-day and total imprecision (CV), assessed from five IQC materials were 
1.9% and 2.0% for 25(OH)D3 and 2.4% and 3.5% for 25(OH)D2, respectively, (Table 3). We 
verified that repeated measurements of native serum samples also produced acceptable 
imprecision: 1.1% for 25(OH)D3 (n = 73) and 2.5% for 25(OH)D2 (n = 26, above the LOQ). 
The candidate RMP meets current imprecision quality goals and is also in agreement with 
the imprecision reported by the two JCTLM-accepted RMP for analysis of 25(OH)D 
metabolites [9,10]. We studied the variability of method performance at different 25(OH)D2 
concentrations using nine different serum materials (6 IQC and 3 SRM) analyzed in at least 
five independent measurement series. The method imprecision becomes more marked as 
25(OH)D2 concentrations fall below 2 nmol/L (see Electronic Supplementary Material Fig. 
S2).
We assessed the trueness of our candidate RMP by using five secondary reference materials, 
NIST SRM 972 and 972a. As shown in Table 4, our mean results were within the 
uncertainty of the NIST certified values. On average, the systematic deviation from the 
target for 25(OH)D3 and 25(OH)D2 was 0.4% and 0.3%, respectively. To assess the method 
performance for 25(OH)D2 at a concentration closer to the patient population, we evaluated 
a secondary reference material, NIST SRM 972a-level 2, the only material currently 
available with a low certified 25(OH)D2 value (± U) (2.0 ± 0.2 nmol/L) [34]. We achieved a 
mean (± U) 25(OH)D2 concentration of 1.97 ± 0.07 nmol/L, with an average deviation from 
the target of −0.03 nmol/L (−1.5%) in multiple measurement series (n = 10 results). This is 
an important assessment for 25(OH)D2, which typically circulates at levels around the LOQ 
or below. We assessed the method performance in a sample with a high 3-epi 25(OH)D3 
concentration (SRM 972a-level 4) in three measurement series. We achieved a mean 
25(OH)D3 concentration of 28.4 nmol/L with −0.9% deviation from the target. Thus, the 
candidate RMP meets the set bias quality goal of 1.7%.
Method comparison
As another way of assessing method trueness, we compared our candidate RMP against a 
JCTLM-recognized RMP [10] using 40 serum samples. The concentration range was 22.5–
198 nmol/L for 25(OH)D3 and 1.7–14.1 nmol/L for 25(OH)D2 (9 samples had 25(OH)D2 
values above the LOQ). A Bland-Altman analysis showed excellent agreement between 
methods with mean bias of −0.9% (95% CI from −1.5 to −0.3 %) for 25(OH)D3, 2.3% (95% 
CI from −1.4 to 6.0%) for 25(OH)D2, and 0.2% (95% CI from −0.4 to 0.8%) for total 
25(OH)D (sum of 25(OH)D2 and 25(OH)D3). The scatter and difference plot are presented 
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in Fig.2. Thus, even with singlicate measurements, the bias goal of <1.7% is met for total 
25(OH)D in this reasonably large set of reference samples. The linear regression analysis 
between the two methods showed excellent agreement (R2=1) with the following equation: 
CDC total 25(OH)D, nmol/L= −1.118+1.0188* Ghent total 25(OH)D, nmol/L. Neither the 
slope nor the intercept were significant.
Uncertainty of measurements
The candidate RMP estimated expanded uncertainties, U, ranged from 2.7% to 3.9% with a 
mean of 3.2% for 25(OH)D3 and from 3.1% to 3.8% with a mean of 3.6% for 25(OH)D2. 
Detailed information is provided in Electronic Supplemental Material, Table S1.
In summary, we developed a highly accurate, International System of Units (SI) mass-
traceable candidate RMP, based on isotope dilution LC-MS/MS, that features good 
sensitivity despite using a relatively small amount of serum and provides high selectivity for 
quantitative analysis of serum concentrations of 25(OH)D3 and 25(OH)D2. The performance 
characteristics of the candidate RMP are comparable to the two currently JCTLM-accepted 
RMPs. The method meets the needs of the CDC’s Vitamin D Standardization Certification 
Program.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Typical selected reaction monitoring chromatogram of serum NIST SRM 972a level 2 with 
25(OH)D3 concentration of 45.1 nmol/L, 3-epi-25(OH)D3 concentration of 3.2 nmol/L and 
25(OH)D2 concentration of 2.0 nmol/L.
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 95% Limits of agreement (−3.6% to 3.9%)
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Table 1
Vitamin D analogs tested for potential interference










Relative retention time is calculated relative to 25(OH)D3 (m/z 383→365) or 25(OH)D2 (m/z 395→377)
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Table 2
Confirmation ion ratios for a candidate reference measurement procedure for the quantitation of 25(OH)D2 





Calibrator 40 3.71 0.57 (0.45–0.68)b
Serum samples 67 LOQ-64.9 0.56 (0.45–0.69)c
25(OH)D3
Calibrators 80 10–100 0.57 (0.49–0.66)d
Serum samples 148 16–183 0.57 (0.51–0.63)c
a
Peak area ratios of confirmation (m/z 383.3→105.0) to quantitation (m/z 383.3→365.1) ions
b
Mean (± 20%) calculated from calibration level 2 in 10 measurement series (2 preparations, 2 injections)
c
Mean (minimum-maximum) from all serum samples with concentrations >LOQ from 5 measurement series
d
Mean (± 15%) calculated from all calibration levels in 5 measurement series (4 levels, 2 preparations, 2 injections)
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Table 3
Imprecision of the candidate reference measurement procedure for quantitation of serum concentrations of 





3.00 1.6 2.8 3.1
3.08 3.8 3.7 4.9
4.66 3.4 3.0 4.1
9.90 1.5 2.9 3.1
14.8 1.7 2.1 2.5
25(OH)D3
23.8 2.3 1.2 2.2
40.6 3.1 1.0 2.7
49.2 0.6 1.5 1.6
65.3 1.8 0.8 1.7
84.5 1.5 2.0 1.8
a
Duplicate samples of internal quality control serum were tested in five independent measurement series. The within-day, between-day imprecision, 
and total CV were calculated for each material using CLSI EP-10-A3 document as a guide [24].
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